BCR-ABL p210 fusion protein(BCR-ABL fusion)

Reference:
Size

100ug, 10ug

Brand

Product type

Host Species

Description of BCR/ABL p210 fusion protein(BCR/ABL fusion)

Description of BCR/ABL p210 fusion protein(BCR/ABL fusion)

General information on BCR-ABL1 protein

BCR-ABL1 is encoded by the BCR-ABL1 fusion gene that results from the genetic material of both chromosome 9 and chromosome 22. The ABL1 gene located on chromosome 9 is juxtaposed onto the breakpoint cluster region of BCR gene which is located on chromosome 22. As such BCR-ABL1 is a hybrid protein and a tyrosine kinase. The protein fusion interrupts the genome stability and causes the cell to divide uncontrollably. The BCR-ABL1 protein complex also impairs a different signaling pathway that regulates the cell cycle.
nBCR-ABL1 protein is phosphorylated by JAK2 protein at Y177. Upon phosphorylation, BCR-ABL1 fusion protein is stabilized which strengthens its tumorigenic cell signaling. JAK2 protein mutations has been linked to aberrant BCR-ABL1 protein activity. JAk/ BCR-ABL1 abnormalities have been involved in increase survival and proliferation of myelogenous leukemia cells and hematologic malignancies. BCR-ABL1 protein complex upregulates JAK-STAT signaling and helps maintain leukemic cell division and growth. For this reason, both JA2 protein and BCR-ABL1 protein have been targets for anti-cancer treatments.
nBCR-ABL protein also activates the Ras/MAPK/ERK pathway. The latter consists of a chain of proteins located on the cell surface that communicate the signal from a receptor on the surface to the nucleus of the cell. This leads to gene transcriptions that results in increased cell proliferation. Ras/MAPK/ERK pathway also increases expression levels of osteopontin (OPN) which indirectly increases the proliferation of leukemic cells. BCR-ABL has also been implicated to higher levels of activated Ras bound to GTP which inhibits cell induced apoptosis. The BCR-ABL induced apoptotic inhibition is resistant to drug-induced apoptosis. The expression levels of pro-apoptotic molecules such as p53, p21 and Bax is increased. However, their activity is impaired, and apoptosis is not carried out. Furthermore, BCR-ABL fusion protein prevent caspase 9 and caspase 3 activity. Both of these proteins are required for efficient apoptosis. Their inhibition further strengthens BCR-ABL fusion protein anti-apoptotic activity.

Product nameBCR-ABL p210 fusion protein(BCR-ABL fusion)
Expression systemProcaryotic expression
Molecular weight23.29kDa
Purity estimated>90% by SDS-PAGE
Buffer0.02% Sarcosyl,PBS,pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection)
BrandProteoGenix
Host speciesEscherichia coli (E.coli)
Fragment TypeGln1-Cys97
Aliases /Synonyms/
ReferencePX-P4738
NoteFor research use only
Product nameBCR-ABL p210 fusion protein(BCR-ABL fusion)
Expression systemProcaryotic expression
Molecular weight23.29kDa
Purity estimated>90% by SDS-PAGE
Buffer0.02% Sarcosyl,PBS,pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection)
BrandProteoGenix
Host speciesEscherichia coli (E.coli)
Fragment TypeGln1-Cys97
Aliases /Synonyms/
ReferencePX-P4738
NoteFor research use only

Reviews

There are no reviews yet.

Be the first to review “BCR-ABL p210 fusion protein(BCR-ABL fusion)”

Your email address will not be published.

Clear
OK

Please select the country of delivery so that we can send you the quotation including shipping costs.

Thank you for your request! You will receive your quotation per e-mail in a few seconds.

If you did not receive your quotation, please check your spam folder.

Contact us to order

+33 (0)3 90 20 54 70

Write us

Categories: